About ADARx Pharmaceuticals ADARx Pharmaceuticals, Inc. is a late-stage clinical biotechnology company dedicated to transforming cutting-edge science into next-generation RNA medicines across a wide ...

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to ...

The British telecom giant has paid back Rs 890 crore to lenders and acquired a stake worth Rs 1,910 crore in Vi ...

Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

J.P. Morgan turned cautious on the eVTOL sector as it attempted to balance the near-term relativeshare price outperformance ...

Allstate, Travelers (NYSE: TRV ), and Chubb were specifically highlighted by the firm as being the most exposed to the California homeowners' market, which is likely to be hit hard by the claims ...

The fires sweeping across Los Angeles are now on track to cause about $20 billion of insured losses, according to an estimate ...

Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases ...

Novel Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy (“SADA PRIT”) platform designed to improve upon traditional radioimmunotherapy by delivering high therapeutic dose while minimizing ...

The $13.7 billion iShares U.S. Equity Factor Rotation Active ETF from BlackRock added $11.7 billion in assets in 2024 after ...

Fully Enrolled Second Cohort in Phase 2 Basket Study of WAL0921 In Chronic Kidney Disease Plans to Initiate Rare Kidney Diseases Cohort in Early 2025 Company to Attend 43rd Annual J.P. Morgan ...

LAS VEGAS, NV / ACCESSWIRE / / Alyea Therapeutics Corporation Inc. ("Alyea" or the "Company"), a subsidiary of Alt 5 Sigma Corporation (NASDAQ:ALTS), announced today its engagement in key events ...